4D Molecular Therapeutics

Unlocking the full potential of genetic medicine in large-market diseases

Pioneering leader in genetic medicines, with proprietary platform based on Nobel Prize-winning technology: 4DMT is applying the principles of directed evolution to invent novel, customized AAV vectors to combat the shortcomings of conventional vectors. With the strategic appointment of three industry veterans and the formation of an Ophthalmology Advisory Board, 4DMT is rapidly advancing its commercialization efforts as it prepares for pivotal Phase 3 trials in 2025.
Quality synthetic vectors fit for purpose: Clinical data supports the therapeutic potential of 4DMT’s innovative approach to genetic medicines, including 4D-150, the company’s lead ophthalmology candidate which has the potential for multi-year to lifelong durability in wet AMD following a single routine injection
- Each 4DMT candidate has been designed with optimized capsids that are delivered by the routine route of administration for each disease – including intravitreal for eye diseases, aerosol for cystic fibrosis (CF), and intravenously for Fabry disease.
Key Events in 2025: Initiation of global 4FRONT Phase 3 clinical trial of 4D-150 in wet AMD in Q1 2025; 52-week landmark analyses for both severe disease activity (Dose Expansion) & broad wet AMD disease activity (Population Extension) cohorts of PRISM Phase 1/2 clinical trial of 4D-150 in February 2025; Initiation of Phase 3 clinical trial of 4D-710 in CF lung disease in H2 2025